ClinicalTrials.gg
CompletedNCT05244759Updated Feb 17, 2022

Mass Balance Recovery, Absorption, Metabolism and Excretion of [14C]-BLU-5937

A Phase 1 interventional study of [14C]-BLU-5937 in Healthy, sponsored by Bellus Health Inc. - a GSK company. Completed at 1 site in United Kingdom. Open to male participants aged 30 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-02-17.

Sponsored by Bellus Health Inc. - a GSK company (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2020, 6 years 1 month ago, and no results have been posted to the registry.
  • Registered 1 year 5 months after the study started (first participant enrolled Aug 2020, registered Feb 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
30 Years to 65 Years
Sex
Male
01

Study summary

This is a single-centre, open-label, non-randomised, single-period, single-dose study in healthy male subjects designed to assess the mass balance recovery, PK, metabolite profile and metabolite identification of [14C]-BLU-5937.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Bellus Health Inc. - a GSK company is the lead sponsor of 19 studies on the registry; none are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 4 (36%) have results posted.

First submitted before Bellus Health Inc. became part of GlaxoSmithKline.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males

Exclusion criteria

Exclusion Criteria:

  • History of cardiovascular, renal, hepatic, chronic respiratory or gastrointestinal disease, neurological or psychiatric disorder,as judged by the investigator
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Arm 1

    Single oral dose of \[14C\]-BLU-5937

    Drug: [14C]-BLU-5937

Interventions

  • Each subject will receive a single oral administration of \[14C\]-BLU-5937 capsule, in the fasted state.

06

What researchers measure

Primary outcomes

  1. Mass balance recovery of total radioactivity in all excreta after a single oral dose of [14C]-BLU-5937

    Mass balance recovery of total radioactivity in all excreta by analysing the total radioactivity and metabolic profile in blood, urine and faeces samples.

    Time frame: 168 hour

07

Study locations

1 site
  • Quotient Sciences
    Nottingham, Ruddington NG11 6JS, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2020 to primary completion in Sep 2020, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2022
First posted
Feb 17, 2022
StartActual
Aug 25, 2020
Primary completionActual
Sep 23, 2020
CompletionActual
Mar 2, 2021
Last update
Feb 17, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05244759
Responsible party
Sponsor
First posted
Feb 17, 2022
Start date
Aug 25, 2020
Primary completion
Sep 23, 2020
Completion
Mar 2, 2021
Last update
Feb 17, 2022

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BLU-5937

Start the discussion